Radioimmunoconjugates for the Treatment of Cancer

Kraeber-Bodéré, Françoise; Bodet-Milin, Caroline; Rousseau, Caroline; Eugène, Thomas; Pallardy, Amandine; Frampas, É.; Carlier, Thomas; Ferrer, Ludovic; Gaschet, Joëlle; Davodeau, François; Gestin, Jean‐François; Faivre-Chauvet, Alain; Barbet, Jacques; Chérel, Michel

doi:10.1053/j.seminoncol.2014.07.004

Cited by 67 publications

(93 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, there are two approved RTX agents for use in B-cell lymphoma: 131 I-tositumomab (Bexxar Ò , GlaxoSmithKline) and 90 Y-ibritumomab tiuxetan (ZevalinÒ, Spectrum) [140]. Several clinical Phase III trials have shown the utility of those agents in treatment of B-cell NHLs [9, [141][142][143]. Unfortunately, 131 I-tositumomab has recently been discontinued by the GlaxoSmithKline (NYSE: GSK) because of low profits.…”

Section: Other Anti-cd20 Moabsmentioning

confidence: 99%

The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma

Smolewski

Robak

2015

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

show abstract

Section: Other Anti-cd20 Moabsmentioning

confidence: 99%

The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma

Smolewski

Robak

2015

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

show abstract

“…This agent is administered to patients with metastatic colorectal cancer to view the extent of metastatic development (39-42); (ii) Ibritumomab tiuxetan is a murine MAB which is labeled with yttrium 90 or Indium 111. These radioactive agents are used for the treatment of patients with non-Hodgkin's lymphoma and often used together with Rituximab which was discussed above (43-45); (iii) Capromab pendetide, a murine MAB, targets prostate membranes and is used to diagnose prostate cancer or determine the extent of cancer eradication following prostatectomy (46)(47)(48); (iv) Tositumomab is a MAB labeled with iodine 131 and is used to treat patients with non-Hodgkin's lymphoma who are unresponsive to standard chemotherapy (49)(50)(51)(52) .…”

Section: Antitumor Monoclonal Antibodies (Mabs)mentioning

confidence: 99%

Monoclonal Antibodies for the Treatment of Cancer

Pento

2017

View full text Add to dashboard Cite

Abstract.Cancer metastasis is responsible for most of the morbidity and mortality associated with cancer. Cancer metastatic progression is a multiple step process which includes enhanced cell proliferation, release of proteolytic enzymes, cell motility and invasion, angiogenesis and establishment of a supportive microenvironment at the sites of metastatic growth (1, 2).Traditional cancer therapy has focused on removal or destruction of tumour cells by surgery, radiation and rather nonselective types of chemotherapy. Surgery and radiation are often effective with tumours which are localized and have not metastasized to multiple sites throughout the body. Chemotherapy appears to be most effective in the treatment of metastatic cancer; however, typical chemotherapeutic agents such as cisplatin, methotrexate, vincristine, 5-fluorouracil among many others, focus on rapidly growing tissues since cancer cells are relatively rapidly growing. Thus, cancer chemotherapy often results in a high incidence of unwanted and damaging side-effects in rapidly-dividing normal tissues, such as blood cells and cells lining gastrointestinal tract.With a greater understanding of cellular chemistry and genomics during the past twenty years, cellular targets that are unique to cancer cells have been identified and chemotherapeutic agents which specifically bind to, destroy or otherwise inactivate these unique cellular targets have been developed. These agents which impede these unique or overexpressed cancer targets tend to be more selective, -thus more effective with fewer side-effects than traditional, nonselective chemotherapy. They target critical checkpoints which are often overexpressed on rapidly growing and malignant cancer cells, such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and tyrosine kinase. Therefore, cancer Immunotherapy is an exciting and relatively new method to selectively block critical checkpoints in the process of cancer development (3, 4).

show abstract

“…Also, patients with leukemias or lymphomas enjoyed more survival benefits from RIT than without RIT treatment [13][14][15]. However, for solid tumor, which are radio-resistant and less accessible to MAbs, a concern remains about limited clinical efficacy [16].…”

Section: Introductionmentioning

confidence: 99%

Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer

Xiao

et al. 2016

Molecules

View full text Add to dashboard Cite

Abstract:The malignant behaviors of solid tumors such as growth, infiltration and metastasis are mainly nourished by tumor neovascularization. Thus, anti-angiogenic therapy is key to controlling tumor progression. Bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) antibody, plus chemotherapy or biological therapy can prolong survival for cancer patients, but treatment-related mortality is a concern. To improve inhibitory effect and decrease side-effects on non-small-cell lung cancer (NSCLC), we used Re-188, which is a β emitting radionuclide, directly labeled with bevacizumab for radioimmunotherapy in a human A549 tumor model. Cytotoxic assay data showed that, after 188 ReO 4 − or 188 Re-bevacizumab at different concentration for 4 and 24 h, a time-and radioactivity does-dependent reduction in cell viability occurred. Also, an apoptosis assay conformed great apoptosis in the 188 Re-bevacizumab group compared with controls and other treatment groups. In vivo, tumor volumes in the 188 Re-bevacizumab (11.1 MBq/mice) group were not reduced but growth was delayed compared with other groups. Thus, 188 Re-bevacizumab enhanced the therapeutic effect of bevacizumab, suggesting a potential therapeutic strategy for NSCLC treatment.

show abstract

Radioimmunoconjugates for the Treatment of Cancer

Cited by 67 publications

References 47 publications

The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma

The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma

Monoclonal Antibodies for the Treatment of Cancer

Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About